metaPreg - Nifedipine (versus unexposed) during pregnancy

Nifedipine (versus unexposed)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
4 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	2.97 [0.54, 16.34]	94%	2 studies	172	180	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
3 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
3 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine death (< 22 weeks)	1.08 [0.10, 11.26]	61%	2 studies	72	197	not evaluable	ROB	-
Late intrauterine deaths (> 22 weeks)	3.40 [0.85, 13.63]	34%	2 studies	14	197	not evaluable	ROB	-
Elective/induced termination of pregnancy	4.38 [2.10, 9.14]	-	1 study	41	76	not evaluable	ROB	8.22 [3.61; .]
1 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
2 non statistically significant endpoints reported in only one study